IONIS PHARMACEUTICALS INC — Director's Dealing 2025

Jan 17, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IONIS PHARMACEUTICALS INC (IONS)
CIK: 0000874015
Period of Report: 2025-01-15

Reporting Person: Monia Brett P (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-01-15	Common Stock	M	73448	$0.0	Acquired	240841	Direct
2025-01-16	Common Stock	S	33445	$32.634	Disposed	207396	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-01-15	Performance Restricted Stock Units	$0.0	A	169950	Acquired		Common Stock (169950)	Direct
2025-01-15	Restricted Stock Unit	$0.0	A	129395	Acquired		Common Stock (129395)	Direct
2025-01-15	Restricted Stock Unit	$0.0	M	73448	Disposed		Common Stock (73448)	Direct

Footnotes

F1: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

F2: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.26 to $33.00 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.

F4: Grant to reporting person of Performance Restricted Stock Units (PRSUs) under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F5: The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated.

F6: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F7: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F8: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.